NCT06073470 Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD
| NCT ID | NCT06073470 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Methylphenidate |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.
Eligibility Criteria
1. Patients with ADHD 1. Inclusion Criteria * Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD. * At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4. * Patients have a Full IQ (FIQ) score greater than 80. 2. Exclusion Criteria * Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders. * Patients have a major disorder of central nervous system, such as epilepsy. * Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases. * Patients have ever received any medication to treat the clinical symptoms of ADHD. 2. Neurotypical participants: 1. Inclusion Criteria * aged 6 to 18 years * All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5. 2. Exclusion Criteria * participants have any disorder of central nervous system or major systemic disease * participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.
Contact & Investigator
Susan Shur-Fen Gau, MD, PhD
STUDY DIRECTOR
Department of Psychiatry, National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT06073470 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Methylphenidate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06073470 currently recruiting?
Yes, NCT06073470 is actively recruiting participants. Contact the research team at cyshang@ntu.edu.tw for enrollment information.
Where is the NCT06073470 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06073470 clinical trial?
NCT06073470 is sponsored by National Taiwan University Hospital. The principal investigator is Susan Shur-Fen Gau, MD, PhD at Department of Psychiatry, National Taiwan University Hospital. The trial plans to enroll 160 participants.